CO6811814A2 - Vacuna de virus dengue inactivado - Google Patents
Vacuna de virus dengue inactivadoInfo
- Publication number
- CO6811814A2 CO6811814A2 CO13277999A CO13277999A CO6811814A2 CO 6811814 A2 CO6811814 A2 CO 6811814A2 CO 13277999 A CO13277999 A CO 13277999A CO 13277999 A CO13277999 A CO 13277999A CO 6811814 A2 CO6811814 A2 CO 6811814A2
- Authority
- CO
- Colombia
- Prior art keywords
- dengue virus
- virus vaccine
- vaccine inactivated
- inactivated
- dengue
- Prior art date
Links
- 229940023605 dengue virus vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490205P | 2011-05-26 | 2011-05-26 | |
| US201161570966P | 2011-12-15 | 2011-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6811814A2 true CO6811814A2 (es) | 2013-12-16 |
Family
ID=46148894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO13277999A CO6811814A2 (es) | 2011-05-26 | 2013-11-26 | Vacuna de virus dengue inactivado |
Country Status (16)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3207936B1 (en) | 2014-11-18 | 2021-04-21 | Shionogi & Co., Ltd. | Stable peptide composition |
| WO2016145149A1 (en) * | 2015-03-11 | 2016-09-15 | The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research | Combination purified inactivated vaccine for flaviviruses |
| EP3316897A4 (en) | 2015-07-02 | 2019-03-13 | Primevax Immuno-Oncology, Inc. | COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS |
| US10765727B2 (en) | 2015-09-26 | 2020-09-08 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for producing dendritic cells |
| GB201522068D0 (en) * | 2015-12-15 | 2016-01-27 | Glaxosmithkline Biolog Sa | Dried composition |
| BE1024160A9 (fr) * | 2015-12-22 | 2017-12-06 | Glaxosmithkline Biologicals Sa | Formulation immunogène |
| US11033615B2 (en) | 2016-05-31 | 2021-06-15 | The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland | Zika virus vaccine and methods of production |
| WO2018093907A1 (en) | 2016-11-16 | 2018-05-24 | PrimeVax Immuno-Oncology, Inc. | Combination immunotherapies for treatment of cancer |
| WO2018129202A1 (en) * | 2017-01-04 | 2018-07-12 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for therapy with dengue virus |
| CN107140625A (zh) * | 2017-06-14 | 2017-09-08 | 中国海洋大学 | 一种利用植物油制备石墨烯薄膜的方法 |
| ES2991988T3 (es) | 2017-10-30 | 2024-12-05 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica |
| CN111526885A (zh) | 2017-11-03 | 2020-08-11 | 武田疫苗股份有限公司 | 寨卡疫苗和免疫原性组合物及其使用方法 |
| CA3084605A1 (en) | 2017-11-30 | 2019-06-06 | Takeda Vaccines, Inc. | Method for inactivating zika virus and related methods |
| CN111447947B (zh) | 2017-12-07 | 2024-01-12 | 默沙东有限责任公司 | 登革病毒疫苗组合物的制剂 |
| AU2020403013A1 (en) * | 2019-12-11 | 2022-06-02 | Ne1 Inc. | Personalized tumor vaccine and use thereof for cancer immunotherapy |
| US20240076631A2 (en) * | 2020-02-27 | 2024-03-07 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
| CN112546213A (zh) * | 2020-12-31 | 2021-03-26 | 中国医学科学院医学生物学研究所 | 一种制备新型冠状病毒疫苗的方法及针对其有效性的评价方法 |
| CN113750228B (zh) * | 2021-09-25 | 2024-02-20 | 大连理工大学 | 一种冷冻保护剂在铝佐剂中的应用 |
| CN115531529A (zh) * | 2022-09-16 | 2022-12-30 | 大连理工大学 | 一种冻干保护剂在含铝佐剂中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6254873B1 (en) * | 1995-04-17 | 2001-07-03 | The United States Of America As Represented By The Secretary Of The Army | Inactivated dengue virus vaccine |
| MXPA03002890A (es) * | 2000-10-02 | 2004-12-03 | Glaxosmithkline Biolog Sa | Preparacion de virus con envolvente dividido. |
| HUE051878T2 (hu) * | 2003-02-10 | 2021-03-29 | Biogen Ma Inc | Immunglobulin készítmény és annak elõállítási módszere |
| EP2811027A1 (en) * | 2004-05-21 | 2014-12-10 | Novartis Vaccines and Diagnostics, Inc. | Alphavirus vectors for RSV and PIV vaccines |
| KR101357685B1 (ko) * | 2005-11-21 | 2014-02-06 | 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 | 재조합 바이러스용 안정화 제형 |
| DK2144998T3 (en) * | 2007-04-06 | 2017-04-10 | Takeda Vaccines Inc | Methods and compositions for live attenuated viruses |
| EP2337847B1 (en) * | 2008-09-29 | 2015-12-02 | Cadila Pharmaceuticals Ltd. | Vaccine adjuvants |
| PE20110992A1 (es) * | 2009-02-17 | 2012-02-12 | Glaxosmithkline Biolog Sa | Composicion inmunogenica que comprende un antigeno del virus del dengue |
| US9005633B2 (en) * | 2009-07-17 | 2015-04-14 | The United States Of America As Represented By The Secretary Of The Navy. | Psoralen-inactivated viral vaccine and method of preparation |
| US8557253B2 (en) * | 2009-10-07 | 2013-10-15 | Sanofi Pasteur Sa | Stabilizing excipient for inactivated whole virus vaccine |
-
2012
- 2012-05-25 WO PCT/EP2012/059879 patent/WO2012160199A1/en not_active Ceased
- 2012-05-25 PE PE2013002709A patent/PE20140646A1/es not_active Application Discontinuation
- 2012-05-25 AU AU2012260807A patent/AU2012260807B2/en not_active Ceased
- 2012-05-25 PH PH1/2013/502442A patent/PH12013502442A1/en unknown
- 2012-05-25 CA CA2837145A patent/CA2837145A1/en not_active Abandoned
- 2012-05-25 CN CN201710173241.XA patent/CN107050445A/zh active Pending
- 2012-05-25 EP EP12723216.3A patent/EP2714076A1/en not_active Withdrawn
- 2012-05-25 CN CN201280031821.0A patent/CN103619349A/zh active Pending
- 2012-05-25 KR KR1020137034545A patent/KR20140033171A/ko not_active Ceased
- 2012-05-25 EA EA201391515A patent/EA201391515A1/ru unknown
- 2012-05-25 SG SG2013084298A patent/SG194950A1/en unknown
- 2012-05-25 BR BR112013030236A patent/BR112013030236A2/pt not_active Application Discontinuation
- 2012-05-25 US US14/119,902 patent/US20140112953A1/en not_active Abandoned
- 2012-05-25 MX MX2013013862A patent/MX349119B/es active IP Right Grant
- 2012-05-25 JP JP2014511908A patent/JP2014515367A/ja active Pending
-
2013
- 2013-11-07 IL IL229307A patent/IL229307A0/en unknown
- 2013-11-26 CO CO13277999A patent/CO6811814A2/es unknown
-
2016
- 2016-08-05 AU AU2016210743A patent/AU2016210743A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2837145A1 (en) | 2012-11-29 |
| AU2016210743A1 (en) | 2016-08-25 |
| EA201391515A1 (ru) | 2014-05-30 |
| BR112013030236A2 (pt) | 2016-12-06 |
| CN103619349A (zh) | 2014-03-05 |
| KR20140033171A (ko) | 2014-03-17 |
| JP2014515367A (ja) | 2014-06-30 |
| US20140112953A1 (en) | 2014-04-24 |
| PH12013502442A1 (en) | 2018-03-21 |
| IL229307A0 (en) | 2014-01-30 |
| WO2012160199A1 (en) | 2012-11-29 |
| MX349119B (es) | 2017-07-12 |
| CN107050445A (zh) | 2017-08-18 |
| AU2012260807B2 (en) | 2016-05-12 |
| EP2714076A1 (en) | 2014-04-09 |
| MX2013013862A (es) | 2014-01-23 |
| PE20140646A1 (es) | 2014-05-29 |
| SG194950A1 (en) | 2013-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6811814A2 (es) | Vacuna de virus dengue inactivado | |
| IL262123A (en) | Influenza virus vaccines and their uses | |
| IL261204A (en) | Influenza virus vaccines and their use | |
| ZA201404797B (en) | Influenza virus vaccines and uses thereof | |
| EP2753345A4 (en) | POLYPEPTIDIMPFSTOFF | |
| IL240488A0 (en) | Immunogenic composition for mers coronavirus infection | |
| IL236838B (en) | Anti-dengue virus antibodies and uses thereof | |
| DK3424532T3 (da) | Influenzavirus-antistofsammensætninger | |
| DK3447131T3 (da) | Influenza a-virusmutanter | |
| HUE042345T2 (hu) | Hepatitisz C vírus inhibitorai | |
| BR112014033077A2 (pt) | combinação de vacina. | |
| EP2595653A4 (en) | INFLUENZA VACCINE | |
| DK2793937T3 (da) | Vacciner mod HPV | |
| CO6821947A2 (es) | Inhibidores del virus de la hepatitis c | |
| DK2935313T3 (da) | Vacciner mod hepatitis B-virus | |
| EP2876161A4 (en) | VACCINE | |
| CO6940424A2 (es) | Inhibidores del virus de la hepatitis c | |
| BR112014005756A2 (pt) | vacina | |
| CO6821952A2 (es) | Inihibidores del virus de la hepatitis c | |
| EP2755680A4 (en) | PARTICULATE VACCINE FORMULATIONS | |
| PL2931304T3 (pl) | Szczepionka wt1 | |
| EP2829281A4 (en) | VACCINE AGAINST LIPOPOLYSACCHARIDES (LPS) | |
| SMT201700046B (it) | Micobatterio ricombinante come vaccino | |
| SG10201702292YA (en) | Novel attenuated dengue virus strains for vaccine application | |
| EP2678043A4 (en) | RECOMBINANT MUMPSVIRUS VACCINE |